Effect of memantine on painful in the diabetic polyneuropathic patients
Abstract
Diabetic peripheral neuropathy (DPN) is one of the most frequent chronic pain symptoms. Several therapeutic modalities have been used for the patients with DPN. In recent years, NMDA receptor antagonists for modulation of excitatory transmission at primary afferent spino-thalamic neuron synapses are being used. It has been shown that NMDA receptor antagonists are as effective as opioid analgesics in cases with chronic pain. The aim of this study was to investigate on the pain effectiveness of NMDA receptor antagonist Memantin at two different doses prospectively. Twenty four type 2 diabetic neuropathy patients were included into the study. The diagnosis of diabetic neuropathy was based on clinical signs and symptoms (history, clinical examination of muscle strength, sensorial and deep tendon reflexes), and electrophysiological tests. Pain complaints of the patients were evaluated by using visual pain scala before and after the treatment. Patients were administered 10 mg Memantin for the first week followed by then 20 mg for consecutive 6 week. Without interruption of treatment 30 mg Memantin for one week and then 40 mg Memantin for 6 week were administered. There was a significant improvement in both treatment groups as compared to control group. Between the treatment groups was significant. It was concluted that; Memantin was effective in reducing neuropathic pain in patients with DPN.
Keywords
Kaynakça
- Harati Y. Diabetic neuropathies: Unanswered questions. Neurol Clin 2007; 25: 303-17.
- Charnogursky G, Lee H, Lopez N. Diabetic neuropathy. Handb Clin Neurol 2014; 120: 773-85.
- Said G. Diabetic neuropathy. Handb Clin Neurol 2013; 115: 579-89.
- Benbow SJ, MacFarlane IA. Painful diabetic neuropathy. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13: 295-308.
- Martin CL, Albers JW. Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 31-8.
- Thomas P, Tomlinson D. Diabetic and hypoglycemic neuropathy. In Dyck P, Thomas P, editors: Peripheral Neuropathy. 3rd ed. Philadelphia: W. B. Saunders Company 1993: 1219-50.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-8.
- Lipton SA. Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004; 1: 101-10.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
20 Ekim 2014
Gönderilme Tarihi
20 Ekim 2014
Kabul Tarihi
-
Yayımlandığı Sayı
Yıl 1970 Cilt: 36 Sayı: 4